← Back to headlines
US FDA warns Novo again about misleading drug advertising - Reuters
US FDA warns Novo Nordisk again about misleading advertising for its diabetes drug Ozempic, according to a letter from the agency seen by Reuters.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
